

Relevant News Sentiment Summary for CUE

Cue Biopharma Announces Pricing of \$12.0 Million Public Offering

Published on: 2024-09-27 03:26:00

Summary: BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE) , a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced the pricing of an underwritten public ...

Sentiment Label: Neutral

Sentiment Score: 0.141241

Topics: Life Sciences, IPO, Financial Markets

[Read more:](#)

Cue Biopharma Announces Proposed Public Offering - Cue Biopharma (NASDAQ:CUE)

Published on: 2024-09-26 20:27:02

Summary: BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.

Sentiment Label: Neutral

Sentiment Score: 0.129795

Topics: Life Sciences, IPO, Financial Markets

[Read more:](#)

Cue Biopharma Announces Proposed Public Offering

Published on: 2024-09-26 20:27:00

Summary: BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE) , a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced that it is commencing an underwritten ...

Sentiment Label: Neutral

Sentiment Score: 0.122833

Topics: Life Sciences, IPO, Financial Markets

[Read more:](#)

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer - Cue Biopharma

Published on: 2024-09-09 12:00:00

Summary: BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. CUE, a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced the appointment of industry veteran Lucinda Warren as ...

Sentiment Label: Bullish

Sentiment Score: 0.407481

Topics: Life Sciences

[Read more:](#)

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

Published on: 2024-09-09 12:00:00

Summary: BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE) , a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced the appointment of industry veteran Lucinda ...

Sentiment Label: Somewhat-Bullish

Sentiment Score: 0.285311

Topics: Life Sciences

[Read more:](#)

Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Published on: 2024-08-19 20:05:00

Summary: BOSTON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE) , a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, provided a business and financial update for the second ...

Sentiment Label: Somewhat-Bullish

Sentiment Score: 0.244605

Topics: Life Sciences, Financial Markets, Earnings

[Read more:](#)

Cue Biopharma, Inc. Reports Q2 Loss, Tops Revenue Estimates - Sol-Gel Technologies (NASDAQ

Published on: 2024-08-15 15:19:44

Summary: Cue Biopharma, Inc. CUE came out with a quarterly loss of \$0.20 per share versus the Zacks Consensus Estimate of a loss of \$0.29. This compares to loss of \$0.29 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of ...

Sentiment Label: Neutral

Sentiment Score: 0.147498

Topics: Earnings, Life Sciences

[Read more:](#)

Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates

Published on: 2024-08-14 23:45:02

Summary: Cue Biopharma (CUE) delivered earnings and revenue surprises of 31.03% and 137.96%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Sentiment Label: Neutral

Sentiment Score: 0.133348

Topics: Earnings, Life Sciences

[Read more:](#)

Cue Biopharma to Host Business Update Call and Webcast - Cue Biopharma (NASDAQ:CUE)

Published on: 2024-08-13 12:00:00

Summary: BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. CUE, a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide ...

Sentiment Label: Somewhat-Bullish

Sentiment Score: 0.298375

Topics: Life Sciences

[Read more:](#)

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates

Published on: 2024-08-08 21:30:10

Summary: Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 8.11% and 37.73%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Sentiment Label: Neutral

Sentiment Score: 0.103221

Topics: Earnings, Life Sciences

[Read more:](#)

EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates

Published on: 2024-08-07 12:15:07

Summary: EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -5.45% and 18.39%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Sentiment Label: Neutral

Sentiment Score: 0.094041

Topics: Earnings, Life Sciences

[Read more:](#)

Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization

Published on: 2024-07-25 20:05:00

Summary: Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncology programs as promising clinical data continues to mature - Company anticipates annualized capital and workforce requirements to be reduced by approximately 25 percent

Sentiment Label: Somewhat-Bullish

Sentiment Score: 0.26346

Topics: Life Sciences

[Read more:](#)

Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock?

Published on: 2024-06-21 11:54:00

Summary: Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Sentiment Label: Somewhat-Bullish

Sentiment Score: 0.217872

Topics: Earnings, Life Sciences

[Read more:](#)

Insmid (INSM) Reports Q1 Loss, Lags Revenue Estimates

Published on: 2024-05-09 12:15:07

Summary: Insmid (INSM) delivered earnings and revenue surprises of 13.11% and 4.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Sentiment Label: Neutral
Sentiment Score: 0.094016
Topics: Earnings, Life Sciences

[Read more:](#)

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

Published on: 2024-05-08 12:00:00

Summary: BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE) , a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will deliver two poster presentations at the ...

Sentiment Label: Neutral
Sentiment Score: 0.134445
Topics: Life Sciences

[Read more:](#)

Here's Why Cue Biopharma (CUE) is Poised for a Turnaround After Losing -22.83% in 4 Weeks

Published on: 2024-04-25 13:35:06

Summary: Cue Biopharma (CUE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near ...

Sentiment Label: Somewhat-Bullish
Sentiment Score: 0.177767
Topics: Earnings, Life Sciences, Financial Markets

[Read more:](#)

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Published on: 2024-04-24 14:01:00

Summary: BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE) , a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present an oral abstract and poster at ...

Sentiment Label: Neutral
Sentiment Score: 0.085862
Topics: Life Sciences

[Read more:](#)

Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now

Published on: 2024-04-15 13:55:03

Summary: Cue Biopharma (CUE) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Sentiment Label: Somewhat-Bullish
Sentiment Score: 0.230094
Topics: Earnings, Life Sciences

[Read more:](#)

Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline

Published on: 2024-03-27 14:00:05

Summary: Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sentiment Label: Neutral
Sentiment Score: 0.098328
Topics: Earnings, Life Sciences

[Read more:](#)

CytomX Therapeutics (CTMX) Lags Q4 Earnings Estimates

Published on: 2024-03-11 21:20:03

Summary: CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -50% and 13.90%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Sentiment Label: Somewhat-Bullish

Sentiment Score: 0.157842

Topics: Earnings, Life Sciences

[Read more:](#)

Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates

Published on: 2024-03-04 22:15:03

Summary: Akoya (AKYA) delivered earnings and revenue surprises of 18.52% and 1.41%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Sentiment Label: Somewhat-Bullish

Sentiment Score: 0.153881

Topics: Earnings, Life Sciences

[Read more:](#)

Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head a

Published on: 2024-02-29 15:00:00

Summary: BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.

Sentiment Label: Neutral

Sentiment Score: 0.086766

Topics: Life Sciences

[Read more:](#)

Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head a

Published on: 2024-02-29 15:00:00

Summary: BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE) , a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that the company's lead clinical asset, CUE-101, will ...

Sentiment Label: Neutral
Sentiment Score: 0.091658
Topics: Life Sciences

[Read more:](#)

Strength Seen in Precision BioSciences (DTIL) : Can Its 20.4% Jump Turn into More Strength?

Published on: 2024-02-27 09:25:00

Summary: Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Sentiment Label: Somewhat-Bullish
Sentiment Score: 0.194418
Topics: Earnings, Life Sciences

[Read more:](#)

Are Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?

Published on: 2023-12-07 14:40:09

Summary: Here is how Corvus Pharmaceuticals (CRVS) and Cue Biopharma, Inc. (CUE) have performed compared to their sector so far this year.

Sentiment Label: Somewhat-Bullish

Sentiment Score: 0.21006

Topics: Earnings, Life Sciences

[Read more:](#)

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

Published on: 2023-11-22 13:00:00

Summary: BOSTON, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE) , a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it will take part in a fireside chat at the JMP Securities ...

Sentiment Label: Somewhat-Bullish

Sentiment Score: 0.296693

Topics: Life Sciences

[Read more:](#)

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit - Cue Biopharm

Published on: 2023-11-22 13:00:00

Summary: BOSTON, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. CUE, a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it will take part in a fireside chat at the JMP Securities Hematology ...

Sentiment Label: Somewhat-Bullish

Sentiment Score: 0.27019

Topics: Life Sciences

[Read more:](#)

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Canc

Published on: 2023-11-03 16:00:00

Summary: BOSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE) , a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today the presentation of new positive data from its ongoing fully ...

Sentiment Label: Neutral
Sentiment Score: 0.126122
Topics: Life Sciences

[Read more:](#)

Acadia (ACAD) Surges 8.3%: Is This an Indication of Further Gains?

Published on: 2023-09-28 09:39:00

Summary: Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Sentiment Label: Neutral
Sentiment Score: 0.146808
Topics: Earnings, Life Sciences

[Read more:](#)

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy o

Published on: 2023-09-27 13:05:00

Summary: BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE) , a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today two ...

Sentiment Label: Neutral
Sentiment Score: 0.126103
Topics: Life Sciences

[Read more:](#)

Cue Biopharma And 2 Other Stocks Under \$3 Insiders Are Buying - Cue Biopharma (NASDAQ:CUEB)

Published on: 2023-08-30 11:49:47

Summary: The Dow Jones closed higher by close to 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Sentiment Label: Somewhat-Bullish
Sentiment Score: 0.20506
Topics: Life Sciences

[Read more:](#)

Harmony Biosciences Holdings, Inc. (HRMY) Lags Q2 Earnings and Revenue Estimates

Published on: 2023-08-01 12:45:09

Summary: Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of -9.68% and 3.99%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Sentiment Label: Neutral
Sentiment Score: 0.148636
Topics: Earnings, Life Sciences

[Read more:](#)

Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent

Published on: 2023-05-25 21:00:00

Summary: As of the data cutoff date, nine of the 14 evaluable patients treated with CUE-101+ KEYTRUDA® (pembrolizumab) demonstrated tumor regression, with five confirmed partial responses (PRs) and three durable stable disease (DSD) responses, two of which have tumor burden reductions of -18% and ...

Sentiment Label: Neutral
Sentiment Score: 0.119314
Topics: Life Sciences

[Read more:](#)

Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates

Published on: 2023-05-09 21:55:11

Summary: Cue Biopharma, Inc. (CUE) delivered earnings and revenue surprises of 12.12% and 37.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Sentiment Label: Neutral
Sentiment Score: 0.121678
Topics: Earnings, Life Sciences

[Read more:](#)

Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

Published on: 2023-05-09 20:35:00

Summary: BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE) , a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, provided a business and ...

Sentiment Label: Somewhat-Bullish
Sentiment Score: 0.178244
Topics: Earnings, Life Sciences

[Read more:](#)

Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates

Published on: 2023-05-03 21:45:10

Summary: Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -37.50% and 11.71%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Sentiment Label: Neutral
Sentiment Score: 0.100988
Topics: Earnings, Life Sciences

[Read more:](#)

Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business

Published on: 2023-03-21 20:10:00

Summary: BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE) , a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, today reported fourth ...

Sentiment Label: Somewhat-Bullish
Sentiment Score: 0.180335
Topics: Earnings, Life Sciences, Financial Markets

[Read more:](#)

Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceuti

Published on: 2023-02-22 13:00:00

Summary: BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE) , a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today a ...

Sentiment Label: Somewhat-Bullish
Sentiment Score: 0.223121
Topics: Life Sciences

[Read more:](#)

Cue Biopharma's Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Present

Published on: 2023-02-16 15:30:00

Summary: BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE) , a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today that the ...

Sentiment Label: Neutral
Sentiment Score: 0.143683
Topics: Life Sciences

[Read more:](#)

Cue Biopharma's Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Present

Published on: 2023-02-16 15:30:00

Summary: Collaboration with the laboratory of Dr. Michael Dustin elucidates the mechanism of action of Immuno-STATs in activating disease-specific T cells by mimicking the natural formation of immune synapses BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.

Sentiment Label: Neutral
Sentiment Score: 0.141182
Topics: Life Sciences

[Read more:](#)

Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board

Published on: 2023-02-16 13:00:00

Summary: BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE) , a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today that ...

Sentiment Label: Neutral

Sentiment Score: 0.074251

Topics: Life Sciences

[Read more:](#)

Cue Biopharma to Present at Two February 2023 Scientific Conferences

Published on: 2023-02-01 13:00:00

Summary: BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE) , a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today that its ...

Sentiment Label: Neutral

Sentiment Score: 0.11827

Topics: Life Sciences

[Read more:](#)

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences - Cue Biopharma (N

Published on: 2022-11-22 13:00:00

Summary: BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.

Sentiment Label: Neutral

Sentiment Score: 0.131218

Topics: Life Sciences

[Read more:](#)

Cue Biopharma Announces \$30 Million Private Investment in Public Equity (PIPE) Financing - Cu

Published on: 2022-11-14 13:20:14

Summary: BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.

Sentiment Label: Somewhat-Bullish
Sentiment Score: 0.16893
Topics: Life Sciences, Financial Markets

[Read more:](#)

Cue Biopharma Announces \$30 Million Private Investment in Public Equity (PIPE) Financing

Published on: 2022-11-14 13:20:00

Summary: BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE) , a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient's body, announced today that it has ...

Sentiment Label: Somewhat-Bullish
Sentiment Score: 0.173894
Topics: Life Sciences, Financial Markets

[Read more:](#)

Lumos Pharma (LUMO) Reports Q3 Loss, Tops Revenue Estimates

Published on: 2022-11-14 12:25:04

Summary: Lumos (LUMO) delivered earnings and revenue surprises of 14.85% and 24.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Sentiment Label: Neutral
Sentiment Score: 0.11016
Topics: Earnings, Life Sciences

[Read more:](#)

Why Soluna Holdings Shares Are Trading Sharply Lower; Here Are 38 Stocks Moving Premarket - A

Published on: 2022-10-24 10:28:56

Summary: Applied Genetic Technologies Corporation AGTC rose 70.8% to \$0.41 in pre-market trading. Syncona disclosed that it will acquire Applied Genetic Technologies Corporation. ASAP, Inc. WTRH shares rose 30.6% to \$0.1846 in pre-market trading. ASAP.com recently launched home & office delivery in New ...

Sentiment Label: Somewhat-Bearish

Sentiment Score: -0.216223

Topics: Financial Markets

[Read more:](#)

Here's Why Cue Biopharma, Inc. (CUE) Looks Ripe for Bottom Fishing

Published on: 2022-08-23 13:55:07

Summary: Cue Biopharma, Inc. (CUE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential ...

Sentiment Label: Somewhat-Bullish

Sentiment Score: 0.196112

Topics: Earnings, Life Sciences

[Read more:](#)

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

Published on: 2022-08-22 23:10:35

Summary: The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet's PODD Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes (T1D) .

Sentiment Label: Neutral

Sentiment Score: 0.123364

Topics: Life Sciences, Financial Markets

[Read more:](#)

Cue Biopharma Shares Decline Following Initial-Stage Metastatic Cancer Study Kicks-off

Published on: 2022-08-22 15:17:57

Summary: Cue Biopharma CUE has dosed the first patient in a Phase 1 dose escalation study evaluating CUE-102 for the treatment of patients with Wilms' Tumor 1 (WT1) -positive recurrent/metastatic cancers.

Sentiment Label: Neutral

Sentiment Score: 0.09282

Topics: Life Sciences, Financial Markets

[Read more:](#)